"ଟୋରେମିଫେନ" ପୃଷ୍ଠାର ସଂସ୍କରଣ‌ଗୁଡ଼ିକ ମଧ୍ୟରେ ତଫାତ

ଉଇକିପିଡ଼ିଆ‌ରୁ
Browse history interactively
← ପୁରୁଣା ବଦଳ
Content deleted Content added
ଭିଜୁଆଲWikitext
{{ଛୋଟ|Toremifene}} ଲେଖାଗଲା
ଟ୍ୟାଗ: 2017 source edit
Fix references, Expend infobox mdwiki.toolforge.org.
 
୧ କ ଧାଡ଼ି: ୧ କ ଧାଡ଼ି:
{{ଛୋଟ|Toremifene}}
{{ଛୋଟ|Toremifene}}
{{Infobox drug
{{Infobox drug
| IUPAC_name = 2-[4-[(1''Z'')-4-Chloro-1,2-diphenyl-but-1-en-1-yl]phenoxy]-''N'',''N''-dimethylethanamine
| IUPAC_name = 2-[4-[(1''Z'')-4-Chloro-1,2-diphenyl-but-1-en-1-yl]phenoxy]-''N'',''N''-dimethylethanamine


<!-- Clinical data -->| image = Toremifene.svg
<!-- Clinical data -->
| image = Toremifene.svg
| width = 250px
| width = 250px
| image2 = Toremifene molecule ball.png
| image2 = Toremifene molecule ball.png
| width2 = 250px
| width2 = 250px


<!-- Names -->| pronounce = {{IPAc-en|ˈ|t|ɔːr|ə|m|ɪ|f|iː|n}}
<!-- Names -->
| pronounce = {{IPAc-en|ˈ|t|ɔːr|ə|m|ɪ|f|iː|n}}
| tradename = Fareston, others
| tradename = Fareston, others
| Drugs.com = {{drugs.com|monograph|fareston}}
| Drugs.com = {{drugs.com|monograph|fareston}}
| MedlinePlus = a608003
| MedlinePlus = a608003


<!-- Legal data -->| licence_EU = yes
<!-- Legal data -->
| licence_EU = yes


<!-- Pharmacokinetic data -->| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
<!-- Pharmacokinetic data -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| pregnancy_category=
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status =
| legal_status =
| routes_of_administration = [[Oral administration|By mouth]]
| routes_of_administration= [[Oral administration|By mouth]]
| bioavailability = Good/~100%<ref name="pmid11108432">{{cite journal | vauthors = Taras TL, Wurz GT, Linares GR, DeGregorio MW | title = Clinical pharmacokinetics of toremifene | journal = Clin Pharmacokinet | volume = 39 | issue = 5 | pages = 327–34 | date = November 2000 | pmid = 11108432 | doi = 10.2165/00003088-200039050-00002 }}</ref><ref name="Jr.Lawrence2015">{{cite book|author1=Vincent T. DeVita Jr.|author2=Theodore S. Lawrence|author3=Steven A. Rosenberg|title=DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology|url=https://books.google.com/books?id=HEAYBgAAQBAJ&pg=PT1126|date=7 January 2015|publisher=Wolters Kluwer Health|isbn=978-1-4698-9455-3|pages=1126–|access-date=25 May 2021|archive-date=14 April 2020|archive-url=https://web.archive.org/web/20200414151036/https://books.google.com/books?id=HEAYBgAAQBAJ&pg=PT1126|url-status=live}}</ref>
| bioavailability = Good/~100%<ref name="pmid11108432">{{cite journal | vauthors = Taras TL, Wurz GT, Linares GR, DeGregorio MW | title = Clinical pharmacokinetics of toremifene | journal = Clin Pharmacokinet | volume = 39 | issue = 5 | pages = 327–34 | date = November 2000 | pmid = 11108432 | doi = 10.2165/00003088-200039050-00002 }}</ref><ref name="Jr.Lawrence2015">{{cite book|author1=Vincent T. DeVita Jr.|author2=Theodore S. Lawrence|author3=Steven A. Rosenberg|title=DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology|url=https://books.google.com/books?id=HEAYBgAAQBAJ&pg=PT1126|date=7 January 2015|publisher=Wolters Kluwer Health|isbn=978-1-4698-9455-3|pages=1126–|access-date=25 May 2021|archive-date=14 April 2020|archive-url=https://web.archive.org/web/20200414151036/https://books.google.com/books?id=HEAYBgAAQBAJ&pg=PT1126|url-status=live}}</ref>
| protein_bound = 99.7%<ref name="pmid11108432" />
| protein_bound = 99.7%<ref name="pmid11108432">{{cite journal | vauthors = Taras TL, Wurz GT, Linares GR, DeGregorio MW | title = Clinical pharmacokinetics of toremifene | journal = Clin Pharmacokinet | volume = 39 | issue = 5 | pages = 327–34 | date = November 2000 | pmid = 11108432 | doi = 10.2165/00003088-200039050-00002 }}</ref>
| metabolism = [[Liver]] ([[CYP3A4]])<ref name="RosenthalBurchum2017" /><ref name="Jr.Lawrence2015" />
| metabolism = [[Liver]] ([[CYP3A4]])<ref name="RosenthalBurchum2017">{{cite book|author1=Laura Rosenthal|author2=Jacqueline Burchum|title=Lehne's Pharmacotherapeutics for Advanced Practice Providers - E-Book|url=https://books.google.com/books?id=gfYoDgAAQBAJ&pg=PA931|date=17 February 2017|publisher=Elsevier Health Sciences|isbn=978-0-323-44779-9|pages=931–|access-date=25 May 2021|archive-date=29 August 2021|archive-url=https://web.archive.org/web/20210829091617/https://books.google.com/books?id=gfYoDgAAQBAJ&pg=PA931|url-status=live}}</ref><ref name="Jr.Lawrence2015">{{cite book|author1=Vincent T. DeVita Jr.|author2=Theodore S. Lawrence|author3=Steven A. Rosenberg|title=DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology|url=https://books.google.com/books?id=HEAYBgAAQBAJ&pg=PT1126|date=7 January 2015|publisher=Wolters Kluwer Health|isbn=978-1-4698-9455-3|pages=1126–|access-date=25 May 2021|archive-date=14 April 2020|archive-url=https://web.archive.org/web/20200414151036/https://books.google.com/books?id=HEAYBgAAQBAJ&pg=PT1126|url-status=live}}</ref>
| metabolites = N-Desmethyltoremifene; 4-Hydroxytoremifene; [[Ospemifene]]<ref name="ChabnerLongo2011">{{cite book|author1=Bruce A. Chabner|author2=Dan L. Longo|title=Cancer Chemotherapy and Biotherapy: Principles and Practice|url=https://books.google.com/books?id=0U4aj4GZWCIC&pg=PA659|date=7 December 2011|publisher=Lippincott Williams & Wilkins|isbn=978-1-4511-4820-6|pages=659–|access-date=25 May 2021|archive-date=20 June 2017|archive-url=https://web.archive.org/web/20170620212114/https://books.google.com/books?id=0U4aj4GZWCIC|url-status=live}}</ref><ref name="Toremifene-Label">{{Cite web |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020497s006lbl.pdf |title=Archive copy |access-date=2021-05-25 |archive-date=2021-03-31 |archive-url=https://web.archive.org/web/20210331062216/https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020497s006lbl.pdf |url-status=live }}</ref>
| metabolites = N-Desmethyltoremifene; 4-Hydroxytoremifene; [[Ospemifene]]<ref name="ChabnerLongo2011">{{cite book|author1=Bruce A. Chabner|author2=Dan L. Longo|title=Cancer Chemotherapy and Biotherapy: Principles and Practice|url=https://books.google.com/books?id=0U4aj4GZWCIC&pg=PA659|date=7 December 2011|publisher=Lippincott Williams & Wilkins|isbn=978-1-4511-4820-6|pages=659–|access-date=25 May 2021|archive-date=20 June 2017|archive-url=https://web.archive.org/web/20170620212114/https://books.google.com/books?id=0U4aj4GZWCIC|url-status=live}}</ref><ref name="Toremifene-Label">{{Cite web |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020497s006lbl.pdf |title=Archive copy |access-date=2021-05-25 |archive-date=2021-03-31 |archive-url=https://web.archive.org/web/20210331062216/https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020497s006lbl.pdf |url-status=live }}</ref>
| onset =
| onset =
| elimination_half-life= Toremifene: 3–7 days<ref name="pmid11108432" /><br />Metabolites: 4–21 days<ref name="Jr.Lawrence2015" /><ref name="Toremifene-Label" /><ref name="pmid11108432" />
| elimination_half-life = Toremifene: 3–7 days<ref name="pmid11108432">{{cite journal | vauthors = Taras TL, Wurz GT, Linares GR, DeGregorio MW | title = Clinical pharmacokinetics of toremifene | journal = Clin Pharmacokinet | volume = 39 | issue = 5 | pages = 327–34 | date = November 2000 | pmid = 11108432 | doi = 10.2165/00003088-200039050-00002 }}</ref><br />Metabolites: 4–21 days<ref name="Jr.Lawrence2015">{{cite book|author1=Vincent T. DeVita Jr.|author2=Theodore S. Lawrence|author3=Steven A. Rosenberg|title=DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology|url=https://books.google.com/books?id=HEAYBgAAQBAJ&pg=PT1126|date=7 January 2015|publisher=Wolters Kluwer Health|isbn=978-1-4698-9455-3|pages=1126–|access-date=25 May 2021|archive-date=14 April 2020|archive-url=https://web.archive.org/web/20200414151036/https://books.google.com/books?id=HEAYBgAAQBAJ&pg=PT1126|url-status=live}}</ref><ref name="Toremifene-Label">{{Cite web |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020497s006lbl.pdf |title=Archive copy |access-date=2021-05-25 |archive-date=2021-03-31 |archive-url=https://web.archive.org/web/20210331062216/https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020497s006lbl.pdf |url-status=live }}</ref><ref name="pmid11108432">{{cite journal | vauthors = Taras TL, Wurz GT, Linares GR, DeGregorio MW | title = Clinical pharmacokinetics of toremifene | journal = Clin Pharmacokinet | volume = 39 | issue = 5 | pages = 327–34 | date = November 2000 | pmid = 11108432 | doi = 10.2165/00003088-200039050-00002 }}</ref>
| duration_of_action =
| duration_of_action=
| excretion = [[Feces]]: 70% (as metabolites)<ref name="Jr.Lawrence2015" />
| excretion = [[Feces]]: 70% (as metabolites)<ref name="Jr.Lawrence2015">{{cite book|author1=Vincent T. DeVita Jr.|author2=Theodore S. Lawrence|author3=Steven A. Rosenberg|title=DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology|url=https://books.google.com/books?id=HEAYBgAAQBAJ&pg=PT1126|date=7 January 2015|publisher=Wolters Kluwer Health|isbn=978-1-4698-9455-3|pages=1126–|access-date=25 May 2021|archive-date=14 April 2020|archive-url=https://web.archive.org/web/20200414151036/https://books.google.com/books?id=HEAYBgAAQBAJ&pg=PT1126|url-status=live}}</ref>


<!-- Chemical and physical data -->| synonyms = (''Z'')-Toremifene; 4-Chlorotamoxifen; 4-CT; Acapodene; CCRIS-8745; FC-1157; FC-1157a; GTx-006; NK-622; NSC-613680
<!-- Chemical and physical data -->
| synonyms = (''Z'')-Toremifene; 4-Chlorotamoxifen; 4-CT; Acapodene; CCRIS-8745; FC-1157; FC-1157a; GTx-006; NK-622; NSC-613680
| C = 26
| C = 26
| Cl = 1
| Cl = 1
| H = 28
| H = 28
| N = 1
| N = 1
| O = 1
| O = 1
| SMILES = ClCCC(/c1ccccc1)=C(/c2ccc(OCCN(C)C)cc2)c3ccccc3
| SMILES = ClCCC(/c1ccccc1)=C(/c2ccc(OCCN(C)C)cc2)c3ccccc3
| StdInChI = 1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-
| StdInChI = 1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-
| StdInChIKey = XFCLJVABOIYOMF-QPLCGJKRSA-N
| StdInChIKey = XFCLJVABOIYOMF-QPLCGJKRSA-N
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| verifiedrevid = 470611877
| verifiedrevid = 470611877
}}
}}


'''ଟୋରେମିଫେନ ('''[[ଇଂରାଜୀ ଭାଷା|ଇଂରାଜୀ ଭାଷାରେ]] '''Toremifene),''' ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ '''ଫାରେଷ୍ଟନ୍''' ଏକ ବେପାର ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ମୁଖ୍ୟତଃ [[ଋତୁବନ୍ଦ]] ମହିଳାମାନଙ୍କର ଆଗେଇ ଯାଇଥିବା ସ୍ତନ କର୍କଟ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।<ref name="AHFS2021">{{Cite web |title=Toremifene Monograph for Professionals |url=https://www.drugs.com/monograph/toremifene.html |url-status=live |archive-url=https://web.archive.org/web/20210120044145/https://www.drugs.com/monograph/toremifene.html |archive-date=20 January 2021 |access-date=8 October 2021 |website=Drugs.com |language=en}}</ref> ଏହା [[ପ୍ରୋସ୍ଟେଟ କର୍କଟ|ପ୍ରୋଷ୍ଟେଟ କର୍କଟର]] ପ୍ରତିରୋଧ ପାଇଁ ମଧ୍ୟ ବ୍ୟବହୃତ ହୋଇପାରେ। <ref name="AHFS2021">{{cite web |title=Toremifene Monograph for Professionals |url=https://www.drugs.com/monograph/toremifene.html |website=Drugs.com |access-date=8 October 2021 |language=en |archive-date=20 January 2021 |archive-url=https://web.archive.org/web/20210120044145/https://www.drugs.com/monograph/toremifene.html |url-status=live }}</ref> ଏହା ପାଟିରେ ଦିଆଯାଏ ।<ref name="AHFS2021">{{cite web |title=Toremifene Monograph for Professionals |url=https://www.drugs.com/monograph/toremifene.html |website=Drugs.com |access-date=8 October 2021 |language=en |archive-date=20 January 2021 |archive-url=https://web.archive.org/web/20210120044145/https://www.drugs.com/monograph/toremifene.html |url-status=live }}</ref>
'''ଟୋରେମିଫେନ ('''[[ଇଂରାଜୀ ଭାଷା|ଇଂରାଜୀ ଭାଷାରେ]] '''Toremifene),''' ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ '''ଫାରେଷ୍ଟନ୍''' ଏକ ବେପାର ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ମୁଖ୍ୟତଃ [[ଋତୁବନ୍ଦ]] ମହିଳାମାନଙ୍କର ଆଗେଇ ଯାଇଥିବା ସ୍ତନ କର୍କଟ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।<ref name="AHFS2021">{{Cite web |title=Toremifene Monograph for Professionals |url=https://www.drugs.com/monograph/toremifene.html |url-status=live |archive-url=https://web.archive.org/web/20210120044145/https://www.drugs.com/monograph/toremifene.html |archive-date=20 January 2021 |access-date=8 October 2021 |website=Drugs.com |language=en}}</ref> ଏହା [[ପ୍ରୋସ୍ଟେଟ କର୍କଟ|ପ୍ରୋଷ୍ଟେଟ କର୍କଟର]] ପ୍ରତିରୋଧ ପାଇଁ ମଧ୍ୟ ବ୍ୟବହୃତ ହୋଇପାରେ। <ref name="AHFS2021" /> ଏହା ପାଟିରେ ଦିଆଯାଏ ।<ref name="AHFS2021" />


ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁହଁ ଗରମ ଯୁକ୍ତ ଲାଲ, ଝାଳ ବୋହିବା, [[ଅଇ|ଅଇ,]] [[ବାନ୍ତି]], ମୁଣ୍ଡ ବୁଲାଇବା, [[ଯୋନୀ ସ୍ରାବ|ଯୋନୀ ସ୍ରାବ ହେବା]] ଏବଂ [[ଯୋନୀପଥ ରକ୍ତସ୍ରାବ|ଯୋନୀ ରକ୍ତସ୍ରାବ]] ହୋଇପାରେ ।<ref name="AHFS2021">{{Cite web |title=Toremifene Monograph for Professionals |url=https://www.drugs.com/monograph/toremifene.html |url-status=live |archive-url=https://web.archive.org/web/20210120044145/https://www.drugs.com/monograph/toremifene.html |archive-date=20 January 2021 |access-date=8 October 2021 |website=Drugs.com |language=en}}<cite class="citation web cs1" data-ve-ignore="true">[https://www.drugs.com/monograph/toremifene.html "Toremifene Monograph for Professionals"]. </cite></ref> ଏହା ରକ୍ତ ଜମାଟ ବାନ୍ଧିବା, [[ଅନିୟମିତ ହୃତ୍ ସ୍ପନ୍ଦନ|ଅନିୟମିତ ହୃଦସ୍ପନ୍ଦନ]], [[ପରଳ|ମୋତିଆବିନ୍ଦୁ]], ଦୃଷ୍ଟିହାନୀ, ଅଧିକ ଯକୃତ ଏନଜାଇମ୍, ଏଣ୍ଡୋମେଟ୍ରିଆଲ୍ ହାଇପରପ୍ଲାସିଆ ଏବଂ [[ଗର୍ଭାଶୟ ଅନ୍ତଃସ୍ତର କର୍କଟ]] ରୋଗ ମଧ୍ୟ ସୃଷ୍ଟି କରିପାରେ ।<ref name="AHFS2021">{{cite web |title=Toremifene Monograph for Professionals |url=https://www.drugs.com/monograph/toremifene.html |website=Drugs.com |access-date=8 October 2021 |language=en |archive-date=20 January 2021 |archive-url=https://web.archive.org/web/20210120044145/https://www.drugs.com/monograph/toremifene.html |url-status=live }}</ref> ଅସ୍ଥି ମେଟାଷ୍ଟାସିସ ଥିବା ମହିଳାମାନଙ୍କଠାରେ [[ହାଇପରକ୍ୟାଲସେମିଆ|ଉଚ୍ଚ ରକ୍ତ କ୍ୟାଲସିୟମ୍ ସ୍ତର]] ହୋଇପାରେ ।<ref name="AHFS2021">{{cite web |title=Toremifene Monograph for Professionals |url=https://www.drugs.com/monograph/toremifene.html |website=Drugs.com |access-date=8 October 2021 |language=en |archive-date=20 January 2021 |archive-url=https://web.archive.org/web/20210120044145/https://www.drugs.com/monograph/toremifene.html |url-status=live }}</ref>
ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁହଁ ଗରମ ଯୁକ୍ତ ଲାଲ, ଝାଳ ବୋହିବା, [[ଅଇ|ଅଇ,]] [[ବାନ୍ତି]], ମୁଣ୍ଡ ବୁଲାଇବା, [[ଯୋନୀ ସ୍ରାବ|ଯୋନୀ ସ୍ରାବ ହେବା]] ଏବଂ [[ଯୋନୀପଥ ରକ୍ତସ୍ରାବ|ଯୋନୀ ରକ୍ତସ୍ରାବ]] ହୋଇପାରେ ।<ref name="AHFS2021" /> ଏହା ରକ୍ତ ଜମାଟ ବାନ୍ଧିବା, [[ଅନିୟମିତ ହୃତ୍ ସ୍ପନ୍ଦନ|ଅନିୟମିତ ହୃଦସ୍ପନ୍ଦନ]], [[ପରଳ|ମୋତିଆବିନ୍ଦୁ]], ଦୃଷ୍ଟିହାନୀ, ଅଧିକ ଯକୃତ ଏନଜାଇମ୍, ଏଣ୍ଡୋମେଟ୍ରିଆଲ୍ ହାଇପରପ୍ଲାସିଆ ଏବଂ [[ଗର୍ଭାଶୟ ଅନ୍ତଃସ୍ତର କର୍କଟ]] ରୋଗ ମଧ୍ୟ ସୃଷ୍ଟି କରିପାରେ ।<ref name="AHFS2021" /> ଅସ୍ଥି ମେଟାଷ୍ଟାସିସ ଥିବା ମହିଳାମାନଙ୍କଠାରେ [[ହାଇପରକ୍ୟାଲସେମିଆ|ଉଚ୍ଚ ରକ୍ତ କ୍ୟାଲସିୟମ୍ ସ୍ତର]] ହୋଇପାରେ ।<ref name="AHFS2021" />


ଏହି ଔଷଧ ହେଉଛି ଏକ ଚୟନ‌କୃତ ଏଷ୍ଟ୍ରୋଜେନ୍ ରିସେପ୍ଟର ମୋଡ୍ୟୁଲେଟର (SERM) ଏବଂ ତେଣୁ ଏହା ଜୈବିକ ଲକ୍ଷଧାରୀ ଏଷ୍ଟ୍ରାଡିଓଲ ଭଳି ଏକ ମିଶ୍ରିତ ଆଗୋନିଷ୍ଟ-ଆଣ୍ଟାଗୋନିଷ୍ଟ ଅଭିଗ୍ରାହକ ।<ref name="RosenthalBurchum2017">{{Cite book|title=Lehne's Pharmacotherapeutics for Advanced Practice Providers - E-Book|url=https://books.google.com/books?id=gfYoDgAAQBAJ&pg=PA931|date=17 February 2017|publisher=Elsevier Health Sciences|isbn=978-0-323-44779-9|pages=931–|access-date=25 May 2021|archive-date=29 August 2021|archive-url=https://web.archive.org/web/20210829091617/https://books.google.com/books?id=gfYoDgAAQBAJ&pg=PA931|url-status=live|last=Laura Rosenthal|last2=Jacqueline Burchum}}</ref> <ref name="SchiffArrillaga2017">{{Cite book |last=David Schiff |url=https://books.google.com/books?id=wQI2DwAAQBAJ&pg=PA296 |title=Cancer Neurology in Clinical Practice: Neurological Complications of Cancer and its Treatment |last2=Isabel Arrillaga |last3=Patrick Y. Wen |date=16 September 2017 |publisher=Humana Press |isbn=978-3-319-57901-6 |pages=296– |access-date=25 May 2021 |archive-url=https://web.archive.org/web/20210829091612/https://books.google.com/books?id=wQI2DwAAQBAJ&pg=PA296 |archive-date=29 August 2021 |url-status=live}}</ref> ଏହାର [[ହାଡ଼]], ଗର୍ଭାଶୟ ଓ [[ଯକୃତ]] ଉପରେ ଏଷ୍ଟ୍ରୋଜେନିକ ପ୍ରଭାବ ଏବଂ [[ସ୍ତନ|ସ୍ତନ ଉପରେରେ]] ଆଣ୍ଟିଏଷ୍ଟ୍ରୋଜେନିକ୍ ପ୍ରଭାବ ରହିଛି ।<ref name="MillerIngle2002">{{Cite book |last=William R. Miller |url=https://books.google.com/books?id=00_LBQAAQBAJ&pg=PA55 |title=Endocrine Therapy in Breast Cancer |last2=James N. Ingle |date=8 March 2002 |publisher=CRC Press |isbn=978-0-203-90983-6 |pages=55–57 |access-date=25 May 2021 |archive-url=https://web.archive.org/web/20200219010243/https://books.google.com/books?id=00_LBQAAQBAJ&pg=PA55 |archive-date=19 February 2020 |url-status=live}}</ref> <ref name="MorrowJordan2003">{{Cite book |last=Monica Morrow |url=https://books.google.com/books?id=HXKibhaF5lMC&pg=PA192 |title=Managing Breast Cancer Risk |last2=Virgil Craig Jordan |publisher=PMPH-USA |year=2003 |isbn=978-1-55009-260-8 |pages=192– |access-date=2021-05-25 |archive-url=https://web.archive.org/web/20210829091612/https://books.google.com/books?id=HXKibhaF5lMC&pg=PA192 |archive-date=2021-08-29 |url-status=live}}</ref> <ref name="ScholarlyEditions2013">{{Cite book |url=https://books.google.com/books?id=AAzZGOf6rl0C&pg=PT51 |title=Selective Estrogen Receptor Modulators—Advances in Research and Application: 2013 Edition: ScholarlyBrief |date=1 May 2013 |publisher=ScholarlyEditions |isbn=978-1-4901-0447-8 |pages=51– |access-date=25 May 2021 |archive-url=https://web.archive.org/web/20210829091613/https://books.google.com/books?id=AAzZGOf6rl0C&pg=PT51 |archive-date=29 August 2021 |url-status=live}}</ref> <ref name="RosenthalBurchum2017">{{cite book|author1=Laura Rosenthal|author2=Jacqueline Burchum|title=Lehne's Pharmacotherapeutics for Advanced Practice Providers - E-Book|url=https://books.google.com/books?id=gfYoDgAAQBAJ&pg=PA931|date=17 February 2017|publisher=Elsevier Health Sciences|isbn=978-0-323-44779-9|pages=931–|access-date=25 May 2021|archive-date=29 August 2021|archive-url=https://web.archive.org/web/20210829091617/https://books.google.com/books?id=gfYoDgAAQBAJ&pg=PA931|url-status=live}}</ref> ଏହା ଏକ ଟ୍ରାଇଫିନାଇଲଏଥିଲିନ୍ ବ୍ୟୁତ୍ପନ୍ନ ଏବଂ [[ଟାମୋକ୍ସିଫେନ|ଟାମୋକ୍ସିଫେନ୍]] ସହିତ ନିବିଡ଼ ସମ୍ପର୍କ ଅଛି ।<ref name="CanoAlsina2006">{{Cite book |last=Antonio Cano |url=https://books.google.com/books?id=heJDAAAAQBAJ&pg=PA52 |title=Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs |last2=Joacquim Calaf i Alsina |last3=Jose Luis Duenas-Diez |date=22 September 2006 |publisher=Springer Science & Business Media |isbn=978-3-540-34742-2 |pages=52– |access-date=25 May 2021 |archive-url=https://web.archive.org/web/20210624212016/https://books.google.com/books?id=heJDAAAAQBAJ&pg=PA52 |archive-date=24 June 2021 |url-status=live}}</ref>
ଏହି ଔଷଧ ହେଉଛି ଏକ ଚୟନ‌କୃତ ଏଷ୍ଟ୍ରୋଜେନ୍ ରିସେପ୍ଟର ମୋଡ୍ୟୁଲେଟର (SERM) ଏବଂ ତେଣୁ ଏହା ଜୈବିକ ଲକ୍ଷଧାରୀ ଏଷ୍ଟ୍ରାଡିଓଲ ଭଳି ଏକ ମିଶ୍ରିତ ଆଗୋନିଷ୍ଟ-ଆଣ୍ଟାଗୋନିଷ୍ଟ ଅଭିଗ୍ରାହକ ।<ref name="RosenthalBurchum2017">{{cite book|author1=Laura Rosenthal|author2=Jacqueline Burchum|title=Lehne's Pharmacotherapeutics for Advanced Practice Providers - E-Book|url=https://books.google.com/books?id=gfYoDgAAQBAJ&pg=PA931|date=17 February 2017|publisher=Elsevier Health Sciences|isbn=978-0-323-44779-9|pages=931–|access-date=25 May 2021|archive-date=29 August 2021|archive-url=https://web.archive.org/web/20210829091617/https://books.google.com/books?id=gfYoDgAAQBAJ&pg=PA931|url-status=live}}</ref> <ref name="SchiffArrillaga2017">{{Cite book |last=David Schiff |url=https://books.google.com/books?id=wQI2DwAAQBAJ&pg=PA296 |title=Cancer Neurology in Clinical Practice: Neurological Complications of Cancer and its Treatment |last2=Isabel Arrillaga |last3=Patrick Y. Wen |date=16 September 2017 |publisher=Humana Press |isbn=978-3-319-57901-6 |pages=296– |access-date=25 May 2021 |archive-url=https://web.archive.org/web/20210829091612/https://books.google.com/books?id=wQI2DwAAQBAJ&pg=PA296 |archive-date=29 August 2021 |url-status=live}}</ref> ଏହାର [[ହାଡ଼]], ଗର୍ଭାଶୟ ଓ [[ଯକୃତ]] ଉପରେ ଏଷ୍ଟ୍ରୋଜେନିକ ପ୍ରଭାବ ଏବଂ [[ସ୍ତନ|ସ୍ତନ ଉପରେରେ]] ଆଣ୍ଟିଏଷ୍ଟ୍ରୋଜେନିକ୍ ପ୍ରଭାବ ରହିଛି ।<ref name="MillerIngle2002">{{Cite book |last=William R. Miller |url=https://books.google.com/books?id=00_LBQAAQBAJ&pg=PA55 |title=Endocrine Therapy in Breast Cancer |last2=James N. Ingle |date=8 March 2002 |publisher=CRC Press |isbn=978-0-203-90983-6 |pages=55–57 |access-date=25 May 2021 |archive-url=https://web.archive.org/web/20200219010243/https://books.google.com/books?id=00_LBQAAQBAJ&pg=PA55 |archive-date=19 February 2020 |url-status=live}}</ref> <ref name="MorrowJordan2003">{{Cite book |last=Monica Morrow |url=https://books.google.com/books?id=HXKibhaF5lMC&pg=PA192 |title=Managing Breast Cancer Risk |last2=Virgil Craig Jordan |publisher=PMPH-USA |year=2003 |isbn=978-1-55009-260-8 |pages=192– |access-date=2021-05-25 |archive-url=https://web.archive.org/web/20210829091612/https://books.google.com/books?id=HXKibhaF5lMC&pg=PA192 |archive-date=2021-08-29 |url-status=live}}</ref> <ref name="ScholarlyEditions2013">{{Cite book |url=https://books.google.com/books?id=AAzZGOf6rl0C&pg=PT51 |title=Selective Estrogen Receptor Modulators—Advances in Research and Application: 2013 Edition: ScholarlyBrief |date=1 May 2013 |publisher=ScholarlyEditions |isbn=978-1-4901-0447-8 |pages=51– |access-date=25 May 2021 |archive-url=https://web.archive.org/web/20210829091613/https://books.google.com/books?id=AAzZGOf6rl0C&pg=PT51 |archive-date=29 August 2021 |url-status=live}}</ref> <ref name="RosenthalBurchum2017" /> ଏହା ଏକ ଟ୍ରାଇଫିନାଇଲଏଥିଲିନ୍ ବ୍ୟୁତ୍ପନ୍ନ ଏବଂ [[ଟାମୋକ୍ସିଫେନ|ଟାମୋକ୍ସିଫେନ୍]] ସହିତ ନିବିଡ଼ ସମ୍ପର୍କ ଅଛି ।<ref name="CanoAlsina2006">{{Cite book |last=Antonio Cano |url=https://books.google.com/books?id=heJDAAAAQBAJ&pg=PA52 |title=Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs |last2=Joacquim Calaf i Alsina |last3=Jose Luis Duenas-Diez |date=22 September 2006 |publisher=Springer Science & Business Media |isbn=978-3-540-34742-2 |pages=52– |access-date=25 May 2021 |archive-url=https://web.archive.org/web/20210624212016/https://books.google.com/books?id=heJDAAAAQBAJ&pg=PA52 |archive-date=24 June 2021 |url-status=live}}</ref>


୧୯୯୬ ମସିହାରେ ୟୁରୋପରେ ଏବଂ ୧୯୯୭ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ପାଇଁ ଟୋରେମିଫେନ ଅନୁମୋଦିତ ହୋଇଥିଲା ।<ref name="EPAR2021">{{Cite web |title=Fareston |url=https://www.ema.europa.eu/en/medicines/human/EPAR/fareston |url-status=live |archive-url=https://web.archive.org/web/20201125065417/https://www.ema.europa.eu/en/medicines/human/EPAR/fareston |archive-date=25 November 2020 |access-date=8 October 2021}}</ref> <ref name="AHFS2021">{{Cite web |title=Toremifene Monograph for Professionals |url=https://www.drugs.com/monograph/toremifene.html |url-status=live |archive-url=https://web.archive.org/web/20210120044145/https://www.drugs.com/monograph/toremifene.html |archive-date=20 January 2021 |access-date=8 October 2021 |website=Drugs.com |language=en}}<cite class="citation web cs1" data-ve-ignore="true">[https://www.drugs.com/monograph/toremifene.html "Toremifene Monograph for Professionals"]. </cite></ref> ୧୯୭୮ ମସିହାରେ ଟାମୋକ୍ସିଫେନ୍ ପରଠାରୁ ଏହା ପ୍ରଥମ ଆଣ୍ଟିଏଷ୍ଟ୍ରୋଜେନ୍ ଭାବରେ ପ୍ରବର୍ତ୍ତିତ ହୋଇଥିଲା ।<ref name="DiSaiaCreasman2017">{{Cite book |last=Philip J. DiSaia |url=https://books.google.com/books?id=MkoQDgAAQBAJ&pg=PA124 |title=Clinical Gynecologic Oncology E-Book |last2=William T. Creasman |last3=Robert S Mannel |last4=D. Scott McMeekin, David G Mutch |date=4 February 2017 |publisher=Elsevier Health Sciences |isbn=978-0-323-44316-6 |pages=124– |access-date=25 May 2021 |archive-url=https://web.archive.org/web/20210829091700/https://books.google.com/books?id=MkoQDgAAQBAJ&pg=PA124 |archive-date=29 August 2021 |url-status=live}}</ref> [[ଯୁକ୍ତରାଷ୍ଟ୍ର ଆମେରିକା|ଯୁକ୍ତରାଷ୍ଟ୍ରରେ]] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ ।<ref name="Drugs.com-Generic">{{Cite news|url=https://www.drugs.com/availability/generic-fareston.html|title=Generic Fareston Availability - Drugs.com|work=Drugs.com|access-date=2019-04-19|archive-url=https://web.archive.org/web/20171229112908/https://www.drugs.com/availability/generic-fareston.html|archive-date=2017-12-29|language=en-US}}</ref> ଯୁକ୍ତରାଜ୍ୟରେ ଏକ ମାସର ଔଷଧ ବ୍ୟବ‌ହାର ପାଇଁ ପ୍ରାୟ ୩୦ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହୁଏ ।<ref name="BNF80">{{Cite book |title=BNF |date=September 2020 - March 2021 |publisher=BMJ Group and the Pharmaceutical Press |year= |isbn=978-0-85711-369-6 |edition=80 |location= |page=1006}}</ref> ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୩୨୫ ଡଲାର ଅଟେ ।<ref>{{Cite web |title=Toremifene Prices, Coupons & Savings Tips - GoodRx |url=https://www.goodrx.com/toremifene#:~:text=About%20Toremifene,average%20retail%20price%20of%20%24978.41. |url-status=live |archive-url=https://web.archive.org/web/20160503044935/http://www.goodrx.com/toremifene#:~:text=About%20Toremifene,average%20retail%20price%20of%20%24978.41. |archive-date=3 May 2016 |access-date=8 October 2021 |website=GoodRx}}</ref>
୧୯୯୬ ମସିହାରେ ୟୁରୋପରେ ଏବଂ ୧୯୯୭ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ପାଇଁ ଟୋରେମିଫେନ ଅନୁମୋଦିତ ହୋଇଥିଲା ।<ref name="EPAR2021">{{Cite web |title=Fareston |url=https://www.ema.europa.eu/en/medicines/human/EPAR/fareston |url-status=live |archive-url=https://web.archive.org/web/20201125065417/https://www.ema.europa.eu/en/medicines/human/EPAR/fareston |archive-date=25 November 2020 |access-date=8 October 2021}}</ref> <ref name="AHFS2021" /> ୧୯୭୮ ମସିହାରେ ଟାମୋକ୍ସିଫେନ୍ ପରଠାରୁ ଏହା ପ୍ରଥମ ଆଣ୍ଟିଏଷ୍ଟ୍ରୋଜେନ୍ ଭାବରେ ପ୍ରବର୍ତ୍ତିତ ହୋଇଥିଲା ।<ref name="DiSaiaCreasman2017">{{Cite book |last=Philip J. DiSaia |url=https://books.google.com/books?id=MkoQDgAAQBAJ&pg=PA124 |title=Clinical Gynecologic Oncology E-Book |last2=William T. Creasman |last3=Robert S Mannel |last4=D. Scott McMeekin, David G Mutch |date=4 February 2017 |publisher=Elsevier Health Sciences |isbn=978-0-323-44316-6 |pages=124– |access-date=25 May 2021 |archive-url=https://web.archive.org/web/20210829091700/https://books.google.com/books?id=MkoQDgAAQBAJ&pg=PA124 |archive-date=29 August 2021 |url-status=live}}</ref> [[ଯୁକ୍ତରାଷ୍ଟ୍ର ଆମେରିକା|ଯୁକ୍ତରାଷ୍ଟ୍ରରେ]] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ ।<ref name="Drugs.com-Generic">{{Cite news|url=https://www.drugs.com/availability/generic-fareston.html|title=Generic Fareston Availability - Drugs.com|work=Drugs.com|access-date=2019-04-19|archive-url=https://web.archive.org/web/20171229112908/https://www.drugs.com/availability/generic-fareston.html|archive-date=2017-12-29|language=en-US}}</ref> ଯୁକ୍ତରାଜ୍ୟରେ ଏକ ମାସର ଔଷଧ ବ୍ୟବ‌ହାର ପାଇଁ ପ୍ରାୟ ୩୦ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହୁଏ ।<ref name="BNF80">{{Cite book |title=BNF |date=September 2020 - March 2021 |publisher=BMJ Group and the Pharmaceutical Press |year= |isbn=978-0-85711-369-6 |edition=80 |location= |page=1006}}</ref> ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୩୨୫ ଡଲାର ଅଟେ ।<ref>{{Cite web |title=Toremifene Prices, Coupons & Savings Tips - GoodRx |url=https://www.goodrx.com/toremifene#:~:text=About%20Toremifene,average%20retail%20price%20of%20%24978.41. |url-status=live |archive-url=https://web.archive.org/web/20160503044935/http://www.goodrx.com/toremifene#:~:text=About%20Toremifene,average%20retail%20price%20of%20%24978.41. |archive-date=3 May 2016 |access-date=8 October 2021 |website=GoodRx}}</ref>


== ଆଧାର ==
== ଆଧାର ==

୧୫:୪୦, ୧୨ ମଇ ୨୦୨୪ ହୋଇଥିବା ରିଭିଜନ

ଟୋରେମିଫେନ
Clinical data
Pronunciation/ˈtɔːrəmɪfiːn/
Trade namesFareston, others
Synonyms(Z)-Toremifene; 4-Chlorotamoxifen; 4-CT; Acapodene; CCRIS-8745; FC-1157; FC-1157a; GTx-006; NK-622; NSC-613680
AHFS/Drugs.commonograph
MedlinePlusa608003
data
Routes of
administration		By mouth
Pharmacokinetic data
BioavailabilityGood/~100%[୩][୨]
Protein binding99.7%[୩]
MetabolismLiver (CYP3A4)[୧][୨]
MetabolitesN-Desmethyltoremifene; 4-Hydroxytoremifene; Ospemifene[୪][୫]
Elimination half-lifeToremifene: 3–7 days[୩]
Metabolites: 4–21 days[୨][୫][୩]
ExcretionFeces: 70% (as metabolites)[୨]
Identifiers
  • 2-[4-[(1Z)-4-Chloro-1,2-diphenyl-but-1-en-1-yl]phenoxy]-N,N-dimethylethanamine
ECHA InfoCard100.125.139 Edit this at Wikidata
Chemical and physical data
FormulaC26H28ClNO
Molar mass୪୦୫.୯୭ g·mol−1
3D model (JSmol)
  • ClCCC(/c1ccccc1)=C(/c2ccc(OCCN(C)C)cc2)c3ccccc3
  • InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25- checkY
  • Key:XFCLJVABOIYOMF-QPLCGJKRSA-N checkY
  (verify)

ଟୋରେମିଫେନ (ଇଂରାଜୀ ଭାଷାରେ Toremifene), ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଫାରେଷ୍ଟନ୍ ଏକ ବେପାର ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ମୁଖ୍ୟତଃ ଋତୁବନ୍ଦ ମହିଳାମାନଙ୍କର ଆଗେଇ ଯାଇଥିବା ସ୍ତନ କର୍କଟ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।[୬] ଏହା ପ୍ରୋଷ୍ଟେଟ କର୍କଟର ପ୍ରତିରୋଧ ପାଇଁ ମଧ୍ୟ ବ୍ୟବହୃତ ହୋଇପାରେ। [୬] ଏହା ପାଟିରେ ଦିଆଯାଏ ।[୬]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁହଁ ଗରମ ଯୁକ୍ତ ଲାଲ, ଝାଳ ବୋହିବା, ଅଇ, ବାନ୍ତି, ମୁଣ୍ଡ ବୁଲାଇବା, ଯୋନୀ ସ୍ରାବ ହେବା ଏବଂ ଯୋନୀ ରକ୍ତସ୍ରାବ ହୋଇପାରେ ।[୬] ଏହା ରକ୍ତ ଜମାଟ ବାନ୍ଧିବା, ଅନିୟମିତ ହୃଦସ୍ପନ୍ଦନ, ମୋତିଆବିନ୍ଦୁ, ଦୃଷ୍ଟିହାନୀ, ଅଧିକ ଯକୃତ ଏନଜାଇମ୍, ଏଣ୍ଡୋମେଟ୍ରିଆଲ୍ ହାଇପରପ୍ଲାସିଆ ଏବଂ ଗର୍ଭାଶୟ ଅନ୍ତଃସ୍ତର କର୍କଟ ରୋଗ ମଧ୍ୟ ସୃଷ୍ଟି କରିପାରେ ।[୬] ଅସ୍ଥି ମେଟାଷ୍ଟାସିସ ଥିବା ମହିଳାମାନଙ୍କଠାରେ ଉଚ୍ଚ ରକ୍ତ କ୍ୟାଲସିୟମ୍ ସ୍ତର ହୋଇପାରେ ।[୬]

ଏହି ଔଷଧ ହେଉଛି ଏକ ଚୟନ‌କୃତ ଏଷ୍ଟ୍ରୋଜେନ୍ ରିସେପ୍ଟର ମୋଡ୍ୟୁଲେଟର (SERM) ଏବଂ ତେଣୁ ଏହା ଜୈବିକ ଲକ୍ଷଧାରୀ ଏଷ୍ଟ୍ରାଡିଓଲ ଭଳି ଏକ ମିଶ୍ରିତ ଆଗୋନିଷ୍ଟ-ଆଣ୍ଟାଗୋନିଷ୍ଟ ଅଭିଗ୍ରାହକ ।[୧] [୭] ଏହାର ହାଡ଼, ଗର୍ଭାଶୟ ଓ ଯକୃତ ଉପରେ ଏଷ୍ଟ୍ରୋଜେନିକ ପ୍ରଭାବ ଏବଂ ସ୍ତନ ଉପରେରେ ଆଣ୍ଟିଏଷ୍ଟ୍ରୋଜେନିକ୍ ପ୍ରଭାବ ରହିଛି ।[୮] [୯] [୧୦] [୧] ଏହା ଏକ ଟ୍ରାଇଫିନାଇଲଏଥିଲିନ୍ ବ୍ୟୁତ୍ପନ୍ନ ଏବଂ ଟାମୋକ୍ସିଫେନ୍ ସହିତ ନିବିଡ଼ ସମ୍ପର୍କ ଅଛି ।[୧୧]

୧୯୯୬ ମସିହାରେ ୟୁରୋପରେ ଏବଂ ୧୯୯୭ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ପାଇଁ ଟୋରେମିଫେନ ଅନୁମୋଦିତ ହୋଇଥିଲା ।[୧୨] [୬] ୧୯୭୮ ମସିହାରେ ଟାମୋକ୍ସିଫେନ୍ ପରଠାରୁ ଏହା ପ୍ରଥମ ଆଣ୍ଟିଏଷ୍ଟ୍ରୋଜେନ୍ ଭାବରେ ପ୍ରବର୍ତ୍ତିତ ହୋଇଥିଲା ।[୧୩] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ ।[୧୪] ଯୁକ୍ତରାଜ୍ୟରେ ଏକ ମାସର ଔଷଧ ବ୍ୟବ‌ହାର ପାଇଁ ପ୍ରାୟ ୩୦ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହୁଏ ।[୧୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୩୨୫ ଡଲାର ଅଟେ ।[୧୬]

ଆଧାର[ସମ୍ପାଦନା]

  1. ↑ ୧.୦ ୧.୧ ୧.୨ Laura Rosenthal; Jacqueline Burchum (17 February 2017). Lehne's Pharmacotherapeutics for Advanced Practice Providers - E-Book. Elsevier Health Sciences. pp. 931–. ISBN 978-0-323-44779-9. Archived from the original on 29 August 2021. Retrieved 25 May 2021.
  2. ↑ ୨.୦ ୨.୧ ୨.୨ ୨.୩ Vincent T. DeVita Jr.; Theodore S. Lawrence; Steven A. Rosenberg (7 January 2015). DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. Wolters Kluwer Health. pp. 1126–. ISBN 978-1-4698-9455-3. Archived from the original on 14 April 2020. Retrieved 25 May 2021.
  3. ↑ ୩.୦ ୩.୧ ୩.୨ ୩.୩ Taras TL, Wurz GT, Linares GR, DeGregorio MW (November 2000). "Clinical pharmacokinetics of toremifene". Clin Pharmacokinet. 39 (5): 327–34. doi:10.2165/00003088-200039050-00002. PMID 11108432.
  4. ↑ Bruce A. Chabner; Dan L. Longo (7 December 2011). Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott Williams & Wilkins. pp. 659–. ISBN 978-1-4511-4820-6. Archived from the original on 20 June 2017. Retrieved 25 May 2021.
  5. ↑ ୫.୦ ୫.୧ "Archive copy" (PDF). Archived (PDF) from the original on 2021-03-31. Retrieved 2021-05-25.{{cite web}}: CS1 maint: archived copy as title (link)
  6. ↑ ୬.୦ ୬.୧ ୬.୨ ୬.୩ ୬.୪ ୬.୫ ୬.୬ "Toremifene Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 20 January 2021. Retrieved 8 October 2021.
  7. ↑ David Schiff; Isabel Arrillaga; Patrick Y. Wen (16 September 2017). Cancer Neurology in Clinical Practice: Neurological Complications of Cancer and its Treatment. Humana Press. pp. 296–. ISBN 978-3-319-57901-6. Archived from the original on 29 August 2021. Retrieved 25 May 2021.
  8. ↑ William R. Miller; James N. Ingle (8 March 2002). Endocrine Therapy in Breast Cancer. CRC Press. pp. 55–57. ISBN 978-0-203-90983-6. Archived from the original on 19 February 2020. Retrieved 25 May 2021.
  9. ↑ Monica Morrow; Virgil Craig Jordan (2003). Managing Breast Cancer Risk. PMPH-USA. pp. 192–. ISBN 978-1-55009-260-8. Archived from the original on 2021-08-29. Retrieved 2021-05-25.
  10. ↑ Selective Estrogen Receptor Modulators—Advances in Research and Application: 2013 Edition: ScholarlyBrief. ScholarlyEditions. 1 May 2013. pp. 51–. ISBN 978-1-4901-0447-8. Archived from the original on 29 August 2021. Retrieved 25 May 2021.
  11. ↑ Antonio Cano; Joacquim Calaf i Alsina; Jose Luis Duenas-Diez (22 September 2006). Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs. Springer Science & Business Media. pp. 52–. ISBN 978-3-540-34742-2. Archived from the original on 24 June 2021. Retrieved 25 May 2021.
  12. ↑ "Fareston". Archived from the original on 25 November 2020. Retrieved 8 October 2021.
  13. ↑ Philip J. DiSaia; William T. Creasman; Robert S Mannel; D. Scott McMeekin, David G Mutch (4 February 2017). Clinical Gynecologic Oncology E-Book. Elsevier Health Sciences. pp. 124–. ISBN 978-0-323-44316-6. Archived from the original on 29 August 2021. Retrieved 25 May 2021.
  14. ↑ "Generic Fareston Availability - Drugs.com". Drugs.com (in ଆମେରିକୀୟ ଇଂରାଜୀ). Archived from the original on 2017-12-29. Retrieved 2019-04-19.
  15. ↑ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1006. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  16. ↑ "Toremifene Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 3 May 2016. Retrieved 8 October 2021.
"https://or.wikipedia.org/w/index.php?title=ଟୋରେମିଫେନ&oldid=539834"ରୁ ଅଣାଯାଇଅଛି